Welcome to our dedicated page for RAPT Therapeutics SEC filings (Ticker: RAPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
RAPT Therapeutics, Inc. filings document the regulatory record of a clinical-stage immunology biopharmaceutical company and its transition from a Nasdaq-listed issuer to a wholly owned subsidiary of GlaxoSmithKline LLC. The record includes Form 8-K disclosures for operating and financial results, Regulation FD presentation materials, material agreements, capital-structure matters, and shareholder-related transaction disclosures.
Later filings include a Form 25 for removal of RAPT common stock from Nasdaq listing and registration, and a Form 15 covering termination of registration or suspension of reporting duties for its common stock. These documents record the completed merger, the surviving-company structure, the delisting process, and Exchange Act reporting-status changes.
RAPT Therapeutics, Inc. is the subject of an all‑cash tender offer by Redrose Acquisition Co., an entity controlled by GlaxoSmithKline, to acquire all outstanding common shares for $58.00 per share.
The filing states the Hart‑Scott‑Rodino waiting period expired February 23, 2026 and the "Regulatory Conditions to the Offer have been satisfied." The filing also reports that, as of February 24, 2026, two state‑court complaints were filed (Morgan and Walsh) alleging negligent misrepresentation and concealment related to the Schedule 14D‑9, and the Company received twelve demand letters alleging disclosure deficiencies.
RAPT Therapeutics, Inc. amended its Schedule 14D-9 to supplement disclosures about the tender offer by a GlaxoSmithKline affiliate to acquire all outstanding common shares for $58.00 per share in cash.
The amendment adds background on a prior $50.00 per‑share proposal from GSK on December 22, 2025, J.P. Morgan’s discounted cash flow implied equity range of $49.45 to $62.05 per share, a precedent‑premium reference range of approximately $50.95 to $73.40 per share, analyst target references (low/high $56.00 to $95.00), and disclosure that J.P. Morgan’s aggregate fee is estimated at $50.4 million. The filing also states the HSR waiting period expired effective February 23, 2026, and notes two complaints and twelve demand letters challenging disclosure; the Company denies those claims.
RTW Investments, LP and Roderick Wong, M.D. reported beneficial ownership of RAPT Therapeutics, Inc. common stock totaling 1,637,165 shares, representing 5.9% of the class. The holdings relate to shares directly held by certain RTW funds advised by RTW Investments.
The ownership percentages are based on 27,710,871 RAPT shares outstanding as of November 3, 2025, as disclosed in the company’s Form 10-Q. Both RTW Investments and Dr. Wong report shared voting and dispositive power over the 1,637,165 shares and no sole voting or dispositive power.
The filers state the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of RAPT Therapeutics.
RAPT Therapeutics, Inc. is the subject of an amended Schedule 13G filing in which Deep Track Capital, Deep Track Biotechnology Master Fund, Ltd., and David Kroin report beneficial ownership of 110,448 shares of common stock, representing 0.40% of the class as of December 31, 2025.
The reporting persons have shared voting and dispositive power over all 110,448 shares and no sole power. The percentage is based on 27,710,871 shares outstanding as of November 3, 2025, as disclosed in the issuer’s Form 10-Q. They certify the holdings are not for the purpose of changing or influencing control of RAPT.
Glazer Capital, LLC and Paul J. Glazer reported beneficial ownership of 1,486,094 shares of RAPT Therapeutics, Inc. common stock, representing 5.36% of the outstanding class.
The shares are held by funds and managed accounts advised by Glazer Capital, with shared voting and dispositive power over all reported shares and no sole authority. The filers state the position is not held to change or influence control of RAPT Therapeutics and is reported on a passive Schedule 13G basis.
RAPT Therapeutics reported an equity grant to director Scott Braunstein. On 01/30/2026, he received 4,956 shares of common stock at a price of $0 per share as a stock-based award, leaving him with 4,956 shares beneficially owned directly.
The award represents the annual grant of restricted stock units (RSUs) under RAPT’s Amended & Restated Non-Employee Director Compensation Policy. These RSUs fully vest on the first anniversary of the grant date, and each RSU converts into one share of common stock upon vesting.
RAPT Therapeutics director Michael F. Giordano reported a stock-based compensation grant. On 01/30/2026 he received 4,956 shares of common stock at a price of $0, reported as directly owned after the transaction.
The footnote explains this represents the annual grant of restricted stock units under the company’s Amended & Restated Non-Employee Director Compensation Policy. These RSUs fully vest on the first anniversary of the grant date, and each unit will deliver one share of common stock upon vesting.
RAPT Therapeutics director Mary Ann Gray received an annual equity grant. On 01/30/2026 she was awarded 4,956 shares of common stock at a grant price of $0, reported as stock under the company’s non-employee director compensation policy.
The award represents 4,956 restricted stock units that fully vest on the first anniversary of the grant date. Each RSU converts into one share of RAPT Therapeutics common stock upon vesting, aligning director compensation with shareholder equity performance.
RAPT Therapeutics director Lori Lyons-Williams reported an annual equity award in the form of restricted stock units. On January 30, 2026, she was granted 4,956 RSUs of RAPT Therapeutics common stock at a price of $0 per unit under the company’s Amended & Restated Non-Employee Director Compensation Policy. These RSUs will fully vest on the first anniversary of the grant date, with each RSU converting into one share of common stock upon vesting. Following this grant, she beneficially owns 4,956 common shares, held directly.
RAPT Therapeutics director Linda Kozick received an annual equity grant in the form of restricted stock units. On 01/30/2026, she was awarded 4,956 RSUs of RAPT common stock at a stated price of $0 per unit under the company’s non-employee director compensation policy.
The RSUs fully vest on the first anniversary of the grant date, and each RSU converts into one share of common stock upon vesting. Following this grant, Kozick beneficially owns 4,956 shares directly through these RSUs.